GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sarepta Therapeutics Inc (NAS:SRPT) » Definitions » EBITDA Margin %

SRPT (Sarepta Therapeutics) EBITDA Margin % : 28.35% (As of Dec. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Sarepta Therapeutics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Sarepta Therapeutics's EBITDA for the three months ended in Dec. 2024 was $187 Mil. Sarepta Therapeutics's Revenue for the three months ended in Dec. 2024 was $658 Mil. Therefore, Sarepta Therapeutics's EBITDA margin for the quarter that ended in Dec. 2024 was 28.35%.


Sarepta Therapeutics EBITDA Margin % Historical Data

The historical data trend for Sarepta Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sarepta Therapeutics EBITDA Margin % Chart

Sarepta Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -86.32 -45.22 -63.76 -36.49 16.66

Sarepta Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.36 13.15 7.47 10.43 28.35

Competitive Comparison of Sarepta Therapeutics's EBITDA Margin %

For the Biotechnology subindustry, Sarepta Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sarepta Therapeutics's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Sarepta Therapeutics's EBITDA Margin % falls into.


;
;

Sarepta Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Sarepta Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=316.889/1901.979
=16.66 %

Sarepta Therapeutics's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=186.673/658.412
=28.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sarepta Therapeutics  (NAS:SRPT) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Sarepta Therapeutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Sarepta Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sarepta Therapeutics Business Description

Address
215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Executives
Claude Nicaise director 215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Wigzell Hans Lennart Rudolf director OSKAR BAECKSTROMSV.11, HAGERSTEN V7 12935
Kathryn Jean Boor director 3736 S. MAIN STREET, MARION NY 14505
Ian Michael Estepan officer: Chief Financial Officer 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
Michael Andrew Chambers director 215 FIRST STREET, CAMBRIDGE MA 02142
Bilal Arif officer: Chief Tech Ops Officer 215 FIRST STREET, CAMBRIDGE MA 02129
Ryan Edward Brown officer: SVP, General Counsel 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
Stephen Mayo director 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Richard Barry director 285 MARGALITA DRIVE, SAN RAFAEL CA 94901
Douglas S Ingram director, officer: President & CEO 2525 DUPONT DR, IRVINE CA 92612
Louise Rodino-klapac officer: Chief Scientific Officer 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
M Kathleen Behrens director 6701 KAISER DRIVE, FREMONT CA 94555
Joseph Bratica officer: Principal Financial Officer 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
David T Howton officer: SVP, General Counsel VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
John C Martin director 333 LAKESIDE DRIVE, FOSTER CITY X1 94404